Medgenics to Present Clinical Data at the 20th Congress of the European Hematology Association

- New Data Presented from Ongoing Phase 1/2 Study of TARGTEPOTM

PHILADELPHIA, June 4, 2015 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE MKT:MDGN), the developer of a proprietary platform for the sustained production and delivery of therapeutic proteins and peptides in patients using ex vivo gene therapy and their own tissue for the treatment of rare and orphan diseases, today announced that clinical data from the ongoing Phase 1/2 study of the Company's TARGTEPOTM (Transduced Autologous Restorative Gene Therapy) system in end stage renal disease will be presented at the 20th Congress of the European Hematology Association (EHA) taking place June 11-14, 2015 in Vienna, Austria.

The data will be presented by Dr. Shany Blum, Vice President of Medical Affairs, during a poster session. Details are as follows:

  • Date & Time: Saturday, June 13, 2015 at 5:15 p.m. CEST
  • Title: A Prospective Clinical Trial of Prolonged Autologous Erythropoietin (EPO) Secretion from TARGTEPO In EPO-Dependent End Stage Renal Disease Patients Showed EPO Independence for Over 8 Months
  • Session: Gene Therapy, Cellular Immunotherapy and Vaccination
  • Abstract: P723
  • Location: Poster area (Hall C)

Presentation materials will be available in the Investor Relations portion of the company's website following conclusion of the session.

About Medgenics, Inc.

Medgenics is developing the TARGT (Transduced Autologous Restorative Gene Therapy) system, a proprietary platform for the sustained production and delivery of therapeutic proteins and peptides using ex vivo gene therapy and the patient's own tissue for the treatment of orphan and rare diseases. For more information, visit the Company's website at

Forward-looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995, which include all statements other than statements of historical fact, including (without limitation) those regarding the Company's financial position, its development and business strategy, its product candidates and the plans and objectives of management for future operations. The Company intends that such forward-looking statements be subject to the safe harbors created by such laws. Forward-looking statements are sometimes identified by their use of the terms and phrases such as "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning, "expect," "believe," "will," "will likely," "should," "could," "would," "may" or the negative of such terms and other comparable terminology. All such forward-looking statements are based on current expectations and are subject to risks and uncertainties. Should any of these risks or uncertainties materialize, or should any of the Company's assumptions prove incorrect, actual results may differ materially from those included within these forward-looking statements. Accordingly, no undue reliance should be placed on these forward-looking statements, which speak only as of the date made. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, the events described in the forward-looking statements contained in this release may not occur.

CONTACT: Medgenics, Inc. John Leaman Brian Piper Stern Investor Relations Beth DelGiacco 212-362-1200

Source:Medgenics, Inc.